SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT

NCT04387695 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma
Portal Vein Thrombosis

Interventions

RADIATION: SBRT+TACE+Sorafenib
DRUG: Sorafenib

Sponsor

First Affiliated Hospital of Zhejiang University